Cepheid Receives Average Rating of “Hold” from Analysts (NASDAQ:CPHD)
Shares of Cepheid (NASDAQ:CPHD) have been given a consensus recommendation of “Hold” by the nineteen analysts that are currently covering the company, ARN reports. Nine analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $48.32.
Cepheid (NASDAQ:CPHD) opened at 38.19 on Tuesday. Cepheid has a one year low of $35.20 and a one year high of $55.89. The stock has a 50-day moving average of $41.3 and a 200-day moving average of $46.46. The company’s market cap is $2.681 billion.
Cepheid (NASDAQ:CPHD) last released its earnings data on Thursday, July 17th. The company reported $0.03 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.16. The company had revenue of $116.50 million for the quarter, compared to the consensus estimate of $115.47 million. During the same quarter last year, the company posted $0.02 earnings per share. Cepheid’s revenue was up 21.4% compared to the same quarter last year. On average, analysts predict that Cepheid will post $-0.52 earnings per share for the current fiscal year.
CPHD has been the subject of a number of recent research reports. Analysts at S&P Equity Research raised their price target on shares of Cepheid from $6.58 to $8.30 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Separately, analysts at ISI Group upgraded shares of Cepheid from a “sell” rating to a “neutral” rating in a research note on Monday, August 11th. They now have a $38.50 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Cepheid in a research note on Friday, August 8th. They now have a $41.00 price target on the stock.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.